GENE ONLINE|News &
Opinion
Blog

2020-12-18| In-DepthSpecial

Coexistence of Thrombophilic Factors and Hemophilia – A Blessing in Disguise?

by GeneOnline
Share To
The most common treatment for hemophilia is a factor replacement therapy, but it comes with challenges like frequent infusions, cost, development of inhibitors, etc. To overcome these limitations, new approaches were explored, such as factors with an extended half-life, inhibition of anticoagulant proteins, and gene therapy.
In normal circumstances, the coexistence of two disorders would enhance distress in an already suffering individual, but what would happen if thrombophilia and hemophilia coexist in an individual? Will they complement each other?

GO Prime with only $1.49 now

LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top